Dasatinib

ALDH1A inhibitor: depletes CD133+cancer stem cells.

ALDH1A inhibitor: depletes CD133+cancer stem cells.

ALDH1A inhibitor: depletes CD133+cancer stem cells.

ALDH1A inhibitor: depletes CD133+cancer stem cells.

General description Medulloblastoma is one of the most common malignant brain tumors in children, with the highest number of diagnoses occurring in patients between 6 and 8 years of age (1). Medulloblastomas are subdivided into four subtypes based

Danusertib is a pan-Aurora kinase inhibitor (IC₅₀s = 13, 79, and 61 nM for Aurora A, B, and C, respectively) that also targets Abl, Ret, TrkA and FGFR1 (IC₅₀s = 25, 31, 31, and 47 nM, respectively). It exhibits

Danusertib is a pan-Aurora kinase inhibitor (IC₅₀s = 13, 79, and 61 nM for Aurora A, B, and C, respectively) that also targets Abl, Ret, TrkA and FGFR1 (IC₅₀s = 25, 31, 31, and 47 nM, respectively). It exhibits

Danusertib is a pan-Aurora kinase inhibitor (IC₅₀s = 13, 79, and 61 nM for Aurora A, B, and C, respectively) that also targets Abl, Ret, TrkA and FGFR1 (IC₅₀s = 25, 31, 31, and 47 nM, respectively). It exhibits

Application Dasatinib has been used: as a protein kinase inhibitor to study its effects on macrophage polarization, lipogenesis, western diet-induced progression of simple steatosis into steatohepatitis (NASH), and liver fibrosis in mice as an

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of &lt:1 nM, 0.8 nM and 79 nM, respectively.Directly targets wild-type and mutant c-Abl kinase domains.

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of &lt:1 nM, 0.8 nM and 79 nM, respectively.Directly targets wild-type and mutant c-Abl kinase domains.

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of &lt:1 nM, 0.8 nM and 79 nM, respectively.Directly targets wild-type and mutant c-Abl kinase domains.